About emtricitabine
Nucleoside reverse transcriptase inhibitor (NRTI)
Used for
- Treats HIV-1 infection with other HIV medicines.
- Helps prevent HIV before exposure (PrEP) in selected people.
Usual adult dose
200 mg by mouth once daily for HIV treatment or PrEP.
Usual dose in children
For HIV treatment: 6 mg/kg once daily, maximum 200 mg; dosing depends on age and formulation.
Common side effects
- Headache
- Diarrhea
- Nausea
- Skin discoloration, especially on palms or soles
Important warnings
- HIV testing is needed before PrEP and regularly during use.
- Stopping treatment can worsen hepatitis B in people with both infections.
- Rarely causes lactic acidosis or serious liver enlargement.
- PrEP does not prevent other sexually transmitted infections.
Pregnancy
Can be used during pregnancy when indicated; discuss treatment choices with a clinician.
Breastfeeding
HIV can pass through breast milk; recommendations depend on local guidance and individual circumstances.
Interactions
- Emtricitabine is eliminated by the kidneys; medicines affecting kidney function may increase risk of side effects.
- Avoid combining with other medicines containing emtricitabine or lamivudine unless specifically directed.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.